The United States Food and Drug Administration (USFDA) has given Zydus Lifesciences final approval to market Silodosin Capsules, 4 mg and 8 mg. The company also received final approval to market Pregabalin Capsules in the following strengths: 25 mg, 50 mg, 75 mg, 100 mg, 150 mg, 200 mg, 225 mg, and 300 mg (USRLD: Lyrica capsules).
Silodosin capsules are used to treat the signs and symptoms of an enlarged prostate gland, also known as benign prostate enlargement (benign prostatic hyperplasia or BPH). According to IQVIA data, silodosin capsules had annual sales of USD 14 million in the United States (IQVIA MAT Sep 2022).
Pregabalin capsules are used to treat pain caused by diabetic nerve damage or shingles (herpes zoster) infection. It is also used to treat nerve pain caused by spinal cord injury and pain in fibromyalgia patients. According to IQVIA data, pregabalin capsules had annual sales of USD 242 million in the United States (IQVIA MAT Sep 2022).